Heidari, A. (2017) Clinical Trials of Dendritic Cell Therapies for Cancer Exposing Vulnerabilities in Human Cancer Cells’ Metabolism and Metabolomics: New Discoveries, Unique Features Inform New Therapeutic Opportunities, Biotech’s Bumpy Road to the Market and Elucidating the Biochemical Programs That Support Cancer Initiation and Progression. Journal of Biological and Medical Sciences, 1, e103.

has been cited by the following article:

• TITLE: In Situ Characterization of Lopinavir by ATR-FTIR Biospectroscopy

  AUTHORS: Alireza Heidari

  KEYWORDS: ATR-FTIR Biospectroscopy, Simulation, Lopinavir, Breakdown, Coronavirus Disease-2019, COVID-19, Infection, Protective and Therapeutic Effect, Potent Drug

  JOURNAL NAME: Computational Chemistry, Vol.8 No.3, July 14, 2020

  ABSTRACT: Lopinavir is an antiretroviral of the protease inhibitor class (Figure 1 and Figure 2). It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir). In the current research, the stimulated ATR-FTIR biospectroscopy of liquid sample of Lopinavir was investigated. The stimulated ATR-FTIR diffractions emitted through focusing the second harmonic laser beam Nd:YAG into the sample were recorded by Echelle spectrometer and ICCD detector. Increasing the energy of laser beam from 2.6 (mJ) to 16 (mJ) led to increase in stimulated ATR-FTIR signal but after breakdown threshold of liquid sample, further increasing energy led to the decrease in stimulating ATR-FTIR signals and for energies higher than 20 (mJ), they were disappeared.